var data={"title":"Vancomycin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vancomycin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7141?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">see &quot;Vancomycin: Drug information&quot;</a> and <a href=\"topic.htm?path=vancomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vancomycin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50667383\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Intraocular Injection Safety Review</span>\n      <span class=\"collapsible-date\">October 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has concluded that the <i>prophylactic</i> use of intraocular vancomycin, alone or in a compounded drug combining multiple active ingredients, during cataract surgery is generally not recommended because of the risk of hemorrhagic occlusive retinal vasculitis (HORV). The FDA recently received an adverse event report concerning a patient who was diagnosed postoperatively with bilateral HORV after being administered injections of Imprimis Pharmaceuticals' compounded triamcinolone, moxifloxacin, and vancomycin formulation in each eye at the conclusion of cataract surgery procedures that were performed 2 weeks apart. The FDA is unaware of any adequately controlled studies demonstrating the safety and efficacy of intraocular vancomycin in preventing endophthalmitis. There is no FDA-approved vancomycin formulation for intraocular injection.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm578743.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPG6jnWVdkJ4rlHSePh6VTLmOhyJ+Nznygvd8P/bvekGQX5dujULjGxVyhOXYIw1Bh9i85TeA+aP+CDg+ZuBgVnneL0HZBXiJJDMfSFPo4jLgBp450LotoVT6T/Z3ONRAnA==&amp;TOPIC_ID=12874\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm578743.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233330\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>First-Vancomycin 25;</li>\n      <li>First-Vancomycin 50;</li>\n      <li>Firvanq;</li>\n      <li>Vancocin HCl;</li>\n      <li>Vancomycin+SyrSpend SF PH4</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233331\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vancocin;</li>\n      <li>Vancomycin Hydrochloride for Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050536\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445215\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection: Note:</b> Serum creatinine concentrations in neonates including VLBW neonates (Bateman 2015) fluctuate within the first 5 to 7 days of life and are generally not reflective of renal function but influenced by maternal transplacental factors. Consider prolongation of dosing interval when coadministered with ibuprofen or indomethacin or in neonates with history of the following: Birth depression, birth hypoxia/asphyxia, or cyanotic congenital heart disease. Monitor serum vancomycin concentrations and adjust accordingly. In neonates, for confirmed or highly suspected MRSA infection, initial targeted trough concentration of ~10 mcg/mL has been suggested to achieve an AUC<sub>24</sub> &gt;400 (with the assumption of MIC &le;1 mcg/mL) (Frymoyer 2014; Stockmann 2015); utilize local antibiogram and protocols for further guidance. <b>Note:</b> Optimal dose and frequency not established in patients receiving ECMO; available data is very limited (Amaker 1996; Buck 1998; Hoie 1990; Mulla 2005). Patient-specific considerations (eg, reason for ECMO) and variability with ECMO procedure itself make extrapolation of pharmacokinetic data and dosing to all patients receiving ECMO difficult; closely monitor serum concentrations and determine individual dosing needs in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Initial dosage recommendations in patients with PNA &le;60 days:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Renal function-based dosing (Bradley 2016; Capparelli 2001; <i>Red Book</i> [AAP 2015]): IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Gestational</p>\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Serum</p>\n            <p style=\"text-indent:0em;\">Creatinine</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dose</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td rowspan=\"5\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;28 weeks</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;0.5 mg/dL</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.5 to 0.7 mg/dL</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg/dose every 24 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.8 to 1 mg/dL</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg/kg/dose every 24 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1.1 to 1.4 mg/dL</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">10 mg/kg/dose every 24 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;1.4 mg/dL</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg/kg/dose every 48 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"5\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;28 weeks</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;0.7 mg/dL</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">0.7 to 0.9 mg/dL</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg/dose every 24 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 1.2 mg/dL</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg/kg/dose every 24 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1.3 to 1.6 mg/dL</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">10 mg/kg/dose every 24 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;1.6 mg/dL</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg/kg/dose every 48 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing (<i>Red Book</i> [AAP 2009]): IV:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Body</p>\n            <p style=\"text-indent:0em;\">Weight</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Postnatal</p>\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1.2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg/kg/dose every 18 to 24 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1.2 to 2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 15 mg/kg/dose every 12 to 18 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 15 mg/kg/dose every 8 to 12 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 15 mg/kg/dose every 8 to 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 15 mg/kg/dose every 6 to 8 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Initial dosage recommendations in patients with PNA &gt;60 days (regardless of GA):</i></b> IV: 15 to 20 mg/kg/dose every 8 hours (Bradley 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS Infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Meningitis (Tunkel 2004): <b>Note:</b> Maintain trough serum concentrations of 15 to 20 mcg/mL; for neonates &lt;2 kg, consider use of smaller doses and longer intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;7 days and &ge;2 kg: IV: 20 to 30 mg/kg/<b>day</b> divided every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &gt;7 days and &ge;2 kg: IV: 30 to 45 mg/kg/<b>day</b> divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">VP-shunt infection, ventriculitis: Limited data available: Intrathecal/intraventricular (<b>use a preservative-free preparation</b>): 5 to 10 mg/day (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Consider single-dose administration with serum concentration monitoring rather than scheduled dosing in patients with urine output &lt;1 mL/kg/hour or if serum creatinine significantly increases from baseline (eg, doubles).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050528\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">see &quot;Vancomycin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: Initial dosage recommendations presented, serum concentrations should be monitored and adjusted accordingly. <b>Note:</b> Doses require adjustment in renal impairment. Consider single-dose administration with serum concentration monitoring rather than scheduled dosing in patients with urine output &lt;1 mL/kg/hour or if serum creatinine significantly increases from baseline (eg, doubles). <b>Note:</b> Optimal dose and frequency not established in patients receiving ECMO; available data is very limited and primarily from neonatal experience (Amaker 1996; Buck 1998; Hoie 1990; Mulla 2005). Patient-specific considerations (eg, reason for ECMO) and variability with ECMO procedure itself make extrapolation of pharmacokinetic data and dosing to all patients receiving ECMO difficult; closely monitor serum concentrations and determine individual dosing needs in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Infants &le;2 months: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed dosing (<i>Red Book </i>[AAP 2015]): <b>Note:</b> Every 6 hour dosing recommended as initial dosage regimen if targeting trough serum concentrations &gt;10 mcg/mL (Benner 2009; Frymoyer 2009) in patients with normal renal function. Close monitoring of serum concentrations and assurance of adequate hydration status is recommended; utilize local antibiogram and protocols for further guidance.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild to moderate infection: IV: 40 to 45 mg/kg/<b>day</b> divided every 6 to 8 hours; dose and frequency should be individualized based on serum concentrations; usual maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe infection: IV: 45 to 60 mg/kg/<b>day</b> divided every 6 to 8 hours; dose and frequency should be individualized based on serum concentrations; usual maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Renal function-based dosing (Bradley 2016; Capparelli 2001; <i>Red Book </i>[AAP 2015]): Gestational age &gt;28 weeks: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">S<sub>cr</sub> &lt;0.7 mg/dL: 15 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">S<sub>cr</sub> 0.7 to 0.9 mg/dL: 20 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">S<sub>cr</sub> 1 to 1.2 mg/dL: 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">S<sub>cr</sub> 1.3 to 1.6 mg/dL: 10 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">S<sub>cr</sub> &gt;1.6 mg/dL: 15 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Infants &gt;2 months (60 days), Children, and Adolescents</i> (<i>Red Book</i> [AAP 2015]): <b>Note:</b> Every 6 hour dosing recommended as initial dosage regimen if targeting trough serum concentrations &gt;10 mcg/mL (Benner 2009; Frymoyer 2009) in patients with normal renal function. Close monitoring of serum concentrations and assurance of adequate hydration status is recommended; utilize local antibiogram and protocols for further guidance.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate infection: IV: 40 to 45 mg/kg/<b>day</b> divided every 6 to 8 hours; dose and frequency should be individualized based on serum concentrations; usual maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe infection: IV: 45 to 60 mg/kg/<b>day</b> divided every 6 to 8 hours; dose and frequency should be individualized based on serum concentrations; usual maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Life-threatening, invasive MRSA infection: Limited data available (Bradley 2016; Le 2013): <b>Note:</b> Dosing based on overall exposure target of AUC/MIC &ge;400 and attainment of AUC/MIC exposure target in 80% to 85% MRSA isolates where institutional epidemiology indicates &le;85% of the isolates have an MIC &ge;1.5 mcg/mL. Initial empiric recommendations are presented, levels should be monitored closely; adjust dose based on serum concentrations, isolate MICs and/or clinical response. Pharmacokinetic simulations showed that dosing every 6 or 8 hours produced similar AUC/MIC exposure but lower trough concentrations were observed with every 8 hour interval (Le 2013); maximum daily dose: 4,000 mg/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants 3 months to Children &lt;2 years: IV:  70 mg/kg/<b>day</b> divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 2 to &lt;12 years: IV: 60 mg/kg/<b>day</b> divided every 6 to 8 hours; higher doses may be considered in the following:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">SCr &lt;0.45 mg/dL: IV: 70 mg/kg/<b>day</b> divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Susceptibility pattern suggests &gt;30% MRSA isolates have MIC &ge;1.5 mcg/mL: IV: 70 mg/kg/<b>day</b> divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;12 years and Adolescents: IV: 60 mg/kg/<b>day</b> divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacteremia [<i>S. aureus</i> (methicillin-resistant)]:</b> Infants, Children, and Adolescents: IV: 15 mg/kg/dose every 6 hours for 2 to 6 weeks depending on severity (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone and joint infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Osteomyelitis [<i>S. aureus</i> (methicillin-resistant)]: Infants, Children, and Adolescents: IV: 15 mg/kg/dose every 6 hours for a minimum of 4 to 6 weeks (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Septic arthritis [<i>S. aureus</i> (methicillin-resistant)]: Infants, Children, and Adolescents: IV: 15 mg/kg/dose every 6 hours for minimum of 3 to 4 weeks  (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>C. difficile</i>-associated diarrhea (CDAD):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-<i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Infants, Children, and Adolescents: Oral: 40 mg/kg/<b>day</b> divided every 6 to 8 hours for 7 to 10 days; maximum daily dose: 2,000 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: Severe or recurrent infection: Infants, Children, and Adolescents: Oral, rectal enema: 40 mg/kg/<b>day</b> in 4 divided doses for &ge;10 days; maximum daily dose: 2,000 mg/<b>day</b>; if complete ileus, rectal enema dosage form may be preferable  (<i>Red Book</i> [AAP 2015]; Schutze 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive:</i> Adolescents: Oral: 125 mg 4 times daily for 10 to 14 days (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Brain abscess, subdural empyema, spinal epidural abscess [<i>S. aureus</i> (methicillin-resistant)]:  Infants, Children, and Adolescents: IV: 15 mg/kg/dose every 6 hours for 4 to 6 weeks (some experts combine with rifampin) (Lui 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis: Infants, Children, and Adolescents: IV: 15 mg/kg/dose every 6 hours; <b>Note:</b> Maintain trough serum concentrations of 15 to 20 mcg/mL (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>S. aureus</i> (methicillin-resistant): Infants, Children, and Adolescents: IV: 15 mg/kg/dose every 6 hours for 2 weeks (some experts combine with rifampin) (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VP-shunt infection, ventriculitis: Limited data available: Infants, Children, and Adolescents: Intrathecal/intraventricular <b>(use a preservative-free preparation)</b>: 5 to 20 mg/<b>day</b>; usual dose: 10 or 20 mg/<b>day</b> (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Empiric therapy/culture negative:</i> Children and Adolescents: IV 60 mg/kg/<b>day</b> divided every 6 hours; maximum daily dose: 2,000 mg/<b>day</b>; use in combination with other antibiotics for at least 4 weeks; longer duration may be required if prosthetic material is present; dosage should be adjusted to target trough serum concentrations of 10 to 15 mcg/mL; higher trough concentrations (15 to 20 mcg/mL) may be needed if there is a lack of response or if a resistant organism (MIC &gt;1 mcg/mL) is identified (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Streptococcus (including enterococcus):</i> Children and Adolescents: IV: 40 mg/kg/<b>day</b> divided every 8 to 12 hours for at least 4 to 6 weeks; a longer duration and additional antibiotics may be required depending on organism and presence of prosthetic material; dosage should be adjusted to target trough serum concentrations of 10 to 15 mcg/mL; higher trough concentrations (15 to 20 mcg/mL) may be needed for resistant organisms (MIC &gt;1 mcg/mL) or if there is a lack of response (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. aureus:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-methicillin resistant: Children and Adolescents: IV: 40 mg/kg/<b>day</b> divided every 8 to 12 hours for at least 4 to 6 weeks; a longer duration and additional antibiotics may be required depending on organism and presence of prosthetic material; dosage should be adjusted to target trough serum concentrations of 10 to 15 mcg/mL; higher trough concentrations (15 to 20 mcg/mL) may be needed for resistant organisms (MIC &gt;1 mcg/mL) or if there is a lack of response (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Methicillin-resistant:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">AHA Guidelines: Children and Adolescents: IV: 40 mg/kg/<b>day</b> divided every 8 to 12 hours for at least 6 weeks; maximum daily dose: 2,000 mg/<b>day;</b> a longer duration may be required depending on the presence of prosthetic material; dosage should be adjusted to target trough serum concentrations of 15 to 20 mcg/mL (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IDSA Guidelines: Infants, Children, and Adolescents: IV: 60 mg/kg/<b>day</b> divided every 6 hours (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Enterocolitis (<i>S. aureus</i>):</b> Infants, Children, and Adolescents: Oral: 40 mg/kg/<b>day</b> divided every 6 to 8 hours for 7 to 10 days; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated (MRSA):</b> Infants, Children, and Adolescents: IV: 40 mg/kg/<b>day</b> divided every 6 to 8 hours (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis)</b> (ISPD [Warady 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis:</i> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Touch contamination of PD line (if known MRSA colonization): Intraperitoneal: 25 mg per liter</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High-risk gastrointestinal procedures: <b>Note:</b> Use should be reserved for patients at high risk for MRSA: IV: 10 mg/kg administered 60 to 90 minutes before procedure; maximum dose: 1,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent: Intraperitoneal: Initial dose: 30 mg/kg in the long dwell; subsequent doses: 15 mg/kg/dose every 3 to 5 days during the long dwell; <b>Note:</b> Increased clearance may occur in patients with residual renal function; subsequent doses should be based on serum concentration obtained 2 to 4 days after the previous dose; redosing should occur when serum concentration &lt;15 mcg/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous: Intraperitoneal: Loading dose: 1,000 mg per liter of dialysate; maintenance dose: 25 mg per liter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Community-acquired pneumonia (CAP):</i> Infants &gt;3 months, Children, and Adolescents: IV: 40 to 60 mg/kg/<b>day</b> every 6 to 8 hours; dosing to achieve AUC/MIC &gt;400 has been recommended for treating moderate to severe MRSA infections (Bradley 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: <i>S. aureus</i> (methicillin-resistant): Infants, Children, and Adolescents: IV: 60 mg/kg/<b>day</b> divided every 6 hours for 7 to 21 days depending on severity (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Health care-associated pneumonia (HAP), <i>S. aureus</i> (methicillin-resistant):</i> Infants, Children, and Adolescents: IV: 60 mg/kg/<b>day</b> divided every 6 hours for 7 to 21 days depending on severity (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Septic thrombosis of cavernous or dural venous sinus [<i>S. aureus</i> (methicillin-resistant)]:</b> Infants, Children, and Adolescents: IV: 15 mg/kg/dose every 6 hours for 4 to 6 weeks (some experts combine with rifampin) (Lui 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections, complicated: [MRSA or <i>S. aureus</i> (methicillin sensitive) in penicillin allergic patients]:</b> Infants, Children, and Adolescents (IDSA [Stevens 2014]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-necrotizing infection: IV: 10 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Necrotizing infection: IV: 15 mg/kg/dose every 6 hours. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: <i>S. aureus</i> (methicillin-resistant):  Infants, Children, and Adolescents: IV: 60 mg/kg/<b>day</b> divided every 6 hours for 7 to 14 days (Liu 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical (perioperative) prophylaxis:</b> Infants, Children, and Adolescents: IV: 15 mg/kg/dose within 120 minutes prior to surgical incision. May be administered in combination with other antibiotics depending upon the surgical procedure (ASHP/IDSA/SIS/SHEA [Bratzler 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Usual dosage range: Note:</b> Initial intravenous dosing should be based on actual body weight; subsequent dosing adjusted based on serum trough vancomycin concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Usual dose: 500 mg every 6 hours or 1,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate recommendations: 15 to 20 mg/kg/dose every 8 to 12 hours (ASHP/IDSA/SIDP [Rybak 2009]); <b>Note:</b> Dose requires adjustment in renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Complicated infections in seriously ill patients: A loading dose of 25 to 30 mg/kg (based on actual body weight) may be used to rapidly achieve target concentrations (ASHP/IDSA/SIDP [Rybak 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 500 to 2,000 mg daily in divided doses every 6 hours. <b>Note:</b> Not appropriate for systemic infections due to low absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment:</b> IV: 15 mg/kg/dose every 12 hours; adjust dose to obtain a trough concentration of 10 to 20 mcg/mL; duration and need for combination therapy is based on valve-type and organism (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: <i>S. aureus (methicillin-resistant):</i> IV: 15 to 20 mg/kg/dose (based on actual body weight) every 8 to 12 hours (IDSA [Lui 2011]); duration and need for combination therapy is based on valve-type</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Group B streptococcus (neonatal prophylaxis):</b> IV: 1,000 mg every 12 hours until delivery. <b>Note:</b> Reserved for penicillin allergic patients at high risk for anaphylaxis if organism is resistant to clindamycin or where no susceptibility data are available (CDC 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections (<i>S. aureus</i> [methicillin-resistant]):</b> IV: 15 to 20 mg/kg/dose every 8 to 12 hours for 7 to 14 days (IDSA [Liu 2011; Stevens 2014]). A loading dose of 25 to 30 mg/kg (based on actual body weight) may be used to rapidly achieve target concentrations in seriously ill patients (ASHP/IDSA/SIDP [Rybak 2009]; IDSA [Liu 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue necrotizing infections due to <i>S. aureus</i> (resistant strains) or polymicrobial (mixed):</b> IV: 15 mg/kg/dose every 12 hours. <b>Note:</b> Give in combination with piperacillin/tazobactam for empiric therapy of polymicrobial [mixed] infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical site infections (trunk or extremity [away from axilla or perineum]):</b> IV: 15 mg/kg/dose every 12 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: <b>Vancomycin levels should be monitored in patients with any renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 10 mg/kg/dose every 6 hours or 15 mg/kg/dose every 8 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 10 mg/kg/dose every 18 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 10 mg/kg/dose; redose based on serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis: 10 mg/kg/dose; redose based on serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): 10 mg/kg/dose; redose based on serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): 10 mg/kg/dose every 12 to 24 hours; monitor serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: Some experts suggest:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;50 mL/minute: Start with 15 to 20 mg/kg/dose (usual: 750 to 1,500 mg) every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 49 mL/minute: Start with 15 to 20 mg/kg/dose (usual: 750 to 1,500 mg) every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;20 mL/minute: Will need longer intervals; determine by serum concentration monitoring</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> In the critically ill patient with renal insufficiency, the initial loading dose (25 to 30 mg/kg) should not be reduced; however, subsequent dosage adjustments should be made based on renal function and trough serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Poorly dialyzable by intermittent hemodialysis (0% to 5%); however, use of high-flux membranes and continuous renal replacement therapy (CRRT) increases vancomycin clearance and generally requires replacement dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Following loading dose of 15 to 25 mg/kg, give either 500 to 1,000 mg or 5 to 10 mg/kg after each dialysis session (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Redosing based on pre-HD serum concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;10 mg/L: Administer 1,000 mg after HD</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">10 to 25 mg/L: Administer 500 to 750 mg after HD</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;25 mg/L: Hold vancomycin</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Redosing based on post-HD serum concentrations: &lt;10 to 15 mg/L: Administer 500 to 1,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Administration via PD fluid: 15 to 30 mg/L (15 to 30 mcg/mL) of PD fluid</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Systemic: Loading dose of 1,000 mg, followed by 500 to 1,000 mg every 48 to 72 hours with close monitoring of levels</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotma 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CVVH: Loading dose of 15 to 25 mg/kg, followed by either 1,000 mg every 48 hours or 10 to 15 mg/kg every 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CVVHD: Loading dose of 15 to 25 mg/kg, followed by either 1,000 mg every 24 hours or 10 to 15 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CVVHDF: Loading dose of 15 to 25 mg/kg, followed by either 1,000 mg every 24 hours or 7.5 to 10 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Consider redosing patients receiving CRRT for vancomycin serum concentrations &lt;10 to 15 mg/L.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: There are no dosage adjustments provided in the manufacturer's labeling; however, degrees of hepatic dysfunction do not affect the pharmacokinetics of vancomycin (Marti 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233306\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vancocin HCl: 125 mg, 250 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mg/100 mL in Dextrose 5% (100 mL); 1000 mg/150 mL in NaCl 0.9% (150 mL); 1000 mg/200 mL in Dextrose 5% (200 mL); 1000 mg/200 mL in NaCl 0.9% (200 mL); 1000 mg/250 mL in Dextrose 5% (250 mL); 1000 mg/250 mL in NaCl 0.9% (250 mL); 1250 mg/150 mL in NaCl 0.9% (150 mL); 1250 mg/250 mL in Dextrose 5% (250 mL); 1250 mg/250 mL in NaCl 0.9% (250 mL); 1500 mg/150 mL in NaCl 0.9% (150 mL); 1500 mg/250 mL in Dextrose 5% (250 mL); 1500 mg/250 mL in NaCl 0.9% (250 mL); 1500 mg/500 mL in Dextrose 5% (500 mL); 1500 mg/500 mL in NaCl 0.9% (500 mL); 1750 mg/250 mL in NaCl 0.9% (250 mL); 1750 mg/300 mL in NaCl 0.9% (300 mL); 1750 mg/500 mL in Dextrose 5% (500 mL); 1750 mg/500 mL in NaCl 0.9% (500 mL); 2000 mg/250 mL in NaCl 0.9% (250 mL); 2000 mg/500 mL in Dextrose 5% (500 mL); 2000 mg/500 mL in NaCl 0.9% (500 mL); 2500 mg/500 mL in NaCl 0.9% (500 mL); 500 mg/100 mL in Dextrose 5% (100 mL); 750 mg/150 mL in Dextrose 5% (150 mL); 750 mg/150 mL in NaCl 0.9% (150 mL); 750 mg/250 mL in NaCl 0.9% (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Vancomycin 25: 25 mg/mL (150 mL, 300 mL) [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate; white grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Vancomycin 50: 50 mg/mL (150 mL, 210 mL, 300 mL) [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate; white grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea [DSC]); 1000 mg (1 ea [DSC]); 5000 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 750 mg (1 ea); 1000 mg (1 ea); 5000 mg (1 ea); 10 g (1 ea); 100 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Firvanq: 25 mg/mL (150 mL, 300 mL); 50 mg/mL (150 mL, 300 mL) [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vancomycin+SyrSpend SF PH4: 50 mg/mL (120 mL, 240 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233291\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45040033\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">see &quot;Vancomycin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">First-Vancomycin oral solution and Vancomycin+SyrSpend SF oral suspension are compounding kits. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51063159\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Firvanq (vancomycin powder for oral solution): FDA approved January 2018; availability anticipated April 2018. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050541\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Oral solution may be compounded or vancomycin powder for injection may be reconstituted and used for oral administration (SHEA/IDSA [Cohen 2010]). The unflavored, diluted solution may also be administered via nasogastric tube.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer intermittent IV infusion over 60 minutes. Red man syndrome may occur if the infusion is too rapid. It is not an allergic reaction, but may be characterized by hypotension and/or a maculopapular rash appearing on the face, neck, trunk, and/or upper extremities; if this should occur, slow the infusion rate to administer dose over 90 to 120 minutes (Healy 1990; Szymusiak-Mutnick 1996) and increase the dilution volume; the reaction usually dissipates in 30 to 60 minutes; administration of antihistamines just before the infusion may also prevent or minimize this reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extravasation treatment: Monitor IV site closely; extravasation will cause serious injury with possible necrosis and tissue sloughing. Rotate infusion site frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal/Intraventricular: Administer as diluted solution (1 to 10 mg/mL) (Al-Jeraisy 2004; Cook 2009; Pfausler 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Instill vancomycin enema solution via rectal foley; retain for 1 hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1671784\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Galaxy containers: Store Galaxy containers at or below -20&deg;C (-4&deg;F). Handle frozen product containers with care; may be fragile in the frozen state. Thaw frozen containers at 25&deg;C (77&deg;F) or 5&deg;C (41&deg;F). Do not immerse in water bath or microwave. Thawed solution in remains chemically stable for 72 hours at 25&deg;C (77&deg;F) or for 30 days when stored at 5&deg;C (41&deg;F). Do not refreeze thawed antibiotics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution (Firvanq): Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) prior to and following reconstitution; discard reconstituted solution after 14 days or if appears hazy or contains particulates. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vials: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). After initial reconstitution with SWFI, solutions are stable for 96 hours if refrigerated. After further dilution with D5W or NS to a concentration of 5 mg/mL, the solution may be stored in a refrigerator for 63 days without significant loss of potency (Das Gupta 1986).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pharmacy bulk packages: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Discard pharmacy bulk packages no later than 4 hours after initial closure puncture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050540\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: Treatment of patients with the following infections or conditions: Infections due to documented or suspected methicillin-resistant <i>S. aureus</i> or beta-lactam resistant coagulase negative <i>Staphylococcus</i>; serious or life-threatening infections (eg, endocarditis, meningitis, osteomyelitis) due to documented or suspected staphylococcal or streptococcal infections in patients who are allergic to penicillins and/or cephalosporins; empiric therapy of infections associated with central lines, VP shunts, hemodialysis shunts, vascular grafts, prosthetic heart valves (FDA approved in all ages). Has also been used for prophylaxis of peritonitis in patients with peritoneal dialysis (PD) catheters undergoing invasive gastrointestinal procedure, touch contamination prophylaxis of PD catheter, and for the treatment of peritonitis in patients with peritoneal catheters</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Treatment of <i>C. difficile</i>-associated diarrhea and enterocolitis caused by <i>Staphylococcus aureus</i> (including methicillin-resistant strains) (FDA approved in pediatric patients [age not specified] and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233387\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV vancomycin may be confused with INVanz</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vancomycin may be confused with clindamycin, gentamicin, tobramycin, valACYclovir, vecuronium, Vibramycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233384\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (accompanied by flushing), local phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills, drug fever</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Eosinophilia, neutropenia (reversible)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Flushing of face and neck (Red man syndrome; may be infusion related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: DRESS syndrome (drug rash with eosinophilia and systemic symptoms), ototoxicity (rare; use of other ototoxic agents may increase risk), renal failure (limited data suggesting direct relationship), Stevens-Johnson syndrome, thrombocytopenia, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, diarrhea, dysgeusia (with oral solution), flatulence, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rare but important or life-threatening: Increased serum creatinine, interstitial nephritis, ototoxicity, renal failure, renal insufficiency, thrombocytopenia, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233314\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to vancomycin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233295\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation and thrombophlebitis: IV vancomycin is an irritant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Pain, tenderness, and necrosis may occur with extravasation. If thrombophlebitis occurs, slow infusion rates, dilute solution (eg, 2.5 to 5 g/L) and rotate infusion sites.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: May cause nephrotoxicity although limited data suggest direct causal relationship; usual risk factors include preexisting renal impairment, concomitant nephrotoxic medications, advanced age, and dehydration. If multiple sequential (&ge;2) serum creatinine concentrations demonstrate an increase of 0.5 mg/dL or &ge;50% increase from baseline (whichever is greater) in the absence of an alternative explanation, the patient should be identified as having vancomycin-induced nephrotoxicity (ASHP/IDSA/SIDP [Rybak 2009]). Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible. Nephrotoxicity has been reported following treatment with oral vancomycin (typically in patients &gt;65 years of age).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neutropenia: Prolonged therapy and use of concomitant drugs that cause neutropenia may increase the risk; monitor leukocyte counts periodically in these patients. Prompt reversal of neutropenia is expected after discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ototoxicity: Ototoxicity is rarely associated with monotherapy. It has been most frequently reported in patients receiving excessive doses, those who have underlying hearing loss, or those receiving concomitant ototoxic drugs (eg, aminoglycosides). Serial auditory function testing may be helpful to minimize risk. Ototoxicity may be transient or permanent; discontinue treatment if signs of ototoxicity occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile </i>infection (CDI); CDI has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inflammatory bowel disease: Clinically significant serum concentrations have been reported in patients with inflammatory disorders of the intestinal mucosa who have taken oral vancomycin (multiple doses) for the treatment of <i>C. difficile</i>-associated diarrhea. Although use may be warranted, the risk for adverse reactions may be higher in this situation; consider monitoring serum trough concentrations, especially with renal insufficiency, severe colitis, concurrent rectal vancomycin administration, and/or concomitant IV aminoglycosides. The Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) suggest that it is appropriate to obtain trough concentrations when a patient is receiving long courses of &ge;2 g/day in adults (SHEA/IDSA [Cohen 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment or those receiving other nephrotoxic or ototoxic drugs; dosage modification required (especially in elderly patients). Accumulation may occur after multiple oral doses of vancomycin in patients with renal impairment; consider monitoring trough concentrations in this circumstance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Oral vancomycin is only indicated for the treatment of CDI or enterocolitis due to <i>S. aureus</i> and is not effective for systemic infections; parenteral vancomycin is not effective for the treatment of enterocolitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Rapid IV administration (eg, over &lt;60 minutes) may result in hypotension, flushing, erythema, urticaria, pruritus and, rarely, cardiac arrest. Reactions usually cease promptly after infusion is stopped. Frequency of infusion reactions may increase with concomitant administration of anesthetics. If used in conjunction with anesthesia, complete the vancomycin infusion prior to anesthesia induction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraocular administration (off-label route): Hemorrhagic occlusive retinal vasculitis (HORV), including permanent visual loss, has been reported in patients receiving intracameral or intravitreal administration of vancomycin during or after cataract surgery. Safety and efficacy of intraocularly administered vancomycin has not been established; vancomycin is not indicated for prophylaxis of endophthalmitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraperitoneal administration (off-label route): Use caution when administering intraperitoneally (IP); in some continuous ambulatory peritoneal dialysis (CAPD) patients, chemical peritonitis (cloudy dialysate, fever, severe abdominal pain) has occurred. Symptoms are self-limited and usually clear after vancomycin discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300205\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233300\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12874&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Vancomycin may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May diminish the therapeutic effect of Vancomycin. Management: Avoid concurrent administration of oral vancomycin and bile acid sequestrants when possible.  If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Vancomycin may enhance the nephrotoxic effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Vancomycin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Vancomycin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piperacillin: May enhance the nephrotoxic effect of Vancomycin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233302\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (oral) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6833811\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in animal reproduction studies. Vancomycin crosses the placenta and can be detected in fetal serum, amniotic fluid, and cord blood (Bourget 1991; Reyes 1989). Adverse fetal effects, including sensorineural hearing loss or nephrotoxicity, have not been reported following maternal use during the second or third trimesters of pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The pharmacokinetics of vancomycin may be altered during pregnancy and pregnant patients may need a higher dose of vancomycin. Maternal half-life is unchanged, but the volume of distribution and the total plasma clearance may be increased (Bourget 1991). Individualization of therapy through serum concentration monitoring may be warranted. Vancomycin is recommended for the treatment of mild, moderate, or severe <i>Clostridium difficile</i> infections in pregnant women (ACG [Surawicz 2013]). Vancomycin is recommended as an alternative agent to prevent the transmission of group B streptococcal (GBS) disease from mothers to newborns (ACOG 2011; CDC 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050535\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic renal function tests (especially when targeting higher serum concentrations), urinalysis, serum vancomycin concentrations, WBC; audiogram (in patients who concurrently receive ototoxic chemotherapy); fluid status </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050539\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Measure trough serum concentrations to assess efficacy. Peak concentrations may be helpful in the setting of atypical pharmacokinetic profile. Trough serum concentration typically obtained at steady state (ie, prior to the fourth dose). Target trough serum concentration may vary depending on organism, MIC, source of infection, and/or other patient factors (Rybak 2009); utilize local antibiogram and protocols for further guidance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">15 to 20 mcg/mL: For organisms with an MIC &ge;1 mcg/mL to meet the target AUC/MIC of &ge;400 in non-neonatal patients (see <b>Note</b>). The American Thoracic Society (ATS) guidelines for hospital-acquired pneumonia and the Infectious Disease Society of America (IDSA) meningitis guidelines also recommend trough concentrations of 15 to 20 mcg/mL. Recommended to improve penetration and improve clinical outcomes for complicated infections (eg, bacteremia, endocarditis, osteomyelitis) caused by <i>S. aureus</i> (Lui 2011; Rybak 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">10 to 15 mcg/mL: Current recommendation for all other infections with an organism with an MIC &lt;1 mcg/mL. In neonates, for confirmed or highly suspected MRSA infection, initial target trough concentration of ~10 mcg/mL is suggested to achieve an AUC<sub>24</sub> &gt;400 for organisms with MIC &le;1 mcg/mL (Frymoyer 2014; Stockmann 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">5 to 10 mcg/mL: Traditional recommendation; may be adequate to treat some infections based on site and MIC; trough likely to be effective in neonates for coagulase negative staphylococcal or enterococcal infections (Bradley 2015); however, this range is not recommended in the adult guidelines for vancomycin use due to resistance development potential</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although AUC/MIC is the preferred pharmacokinetic-pharmacodynamic parameter used to determine clinical effectiveness, trough serum concentrations may be used as a surrogate marker for AUC and are recommended as the most accurate and practical method of vancomycin monitoring (Lui 2011; Rybak 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233294\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by blocking glycopeptide polymerization through binding tightly to D-alanyl-D-alanine portion of cell wall precursor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233313\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Displays time-dependent antimicrobial killing; slowly bacteriocidal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Poor; Rectal: significant absorption through inflamed colonic mucosa may occur; Intraperitoneal (IP): 60% of an IP dose absorbed in 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributes widely in body tissue and fluids, except for CSF</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonate, term: 0.57 to 0.69 L/kg (de Hoog 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates, receiving ECMO (mean age: ~39 weeks): Variable; 1.1 L/kg (range: 0.6 to 2.1 L/kg) (Amaker 1996); others have reported lower values: 0.45 &plusmn; 0.18 L/kg (Buck 1998), 0.67 &plusmn; 0.15 L/kg (Mulla 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pediatric patients: Median: 0.57 L/kg (range: 0.26 to 1.05 L/kg) (Marsot 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 0.4 to 1 L/kg (ASHP/IDSA/SIDP [Rybak 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relative diffusion from blood into CSF: Good only with inflammation (exceeds usual MICs)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CSF concentrations: 0.2 to 17.3 mcg/mL (de Hoog 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CSF:blood level ratio: Normal meninges: Nil; Inflamed meninges: 7.1% to 68% (de Hoog 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Uninflamed meninges: 0 to 4 mcg/mL; serum concentration dependent (ASHP/IDSA/SIDP [Rybak 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Inflamed meninges: 6 to 11 mcg/mL; serum concentration dependent (ASHP/IDSA/SIDP [Rybak 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CSF:serum level ratio: Normal meninges: Nil; Inflamed meninges: ~80% (Shokouhi 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~55%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: No apparent metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Biphasic: Terminal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Newborns: 6 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates receiving ECMO: 6.53 &plusmn; 2.1 hours (Buck 1998); others have reported longer: 10.4 &plusmn; 6.7 hours (Mulla 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 3 months to 4 years: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &gt;3 years: 2.2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 4 to 6 hours; significantly prolonged with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD): 7.5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IV: Immediately after completion of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily via glomerular filtration; IV: Urine (75% as unchanged drug in the first 24 hours); Oral: Primarily feces</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: presence of malignancy in children is associated with an increase in vancomycin clearance</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates: 0.63 to 1.5 mL/minute/kg; dependent on GA and/or PMA (de Hoog 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates, receiving ECMO: ~0.79 mL/minute/kg (Amaker 1996; Buck 1998); others have reported a slightly slower rate: 0.67 mL/minute/kg (Mulla 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pediatric patients: Median: 1.1 mL/minute/kg (range: 0.33 to 1.87 mL/minute/kg) (Marsot 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 0.71 to 1.31 mL/minute/kg (de Hoog 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14320792\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> A vancomycin (25 mg/mL or 50 mg/mL) suspension is commercially available as a compounding kit (First-Vancomycin).</p>\n    <p style=\"text-indent:0em;\">Using a vial of vancomycin powder for injection (reconstituted to 50 mg/mL), add the appropriate volume for the dose to 30 mL of water and administer orally or via NG tube. For oral administration, common flavoring syrups may be added to improve taste.</p>\n    <div class=\"reference\">Vancomycin Hydrochloride for Injection, USP (prescribing information), Schaumburg, Il, APP Pharmaceuticals, LLC, 2011.</div>\r\n\n    <p style=\"text-indent:0em;margin-top:2em;\">A vancomycin 25 mg/mL solution in Ora-Sweet&reg; and water (1:1) may be prepared by reconstituting vancomycin for injection with sterile water, then dilute with a 1:1 mixture of Ora-Sweet&reg; and distilled water to a final concentration of 25 mg/mL; transfer to amber prescription bottle. Stable for 75 days refrigerated or for 26 days at room temperature.</p>\n    <div class=\"reference\">Ensom MH, Decarie D, and Lakhani A, &ldquo;Stability of Vancomycin 25 mg/mL in Ora-Sweet and Water in Unit-Dose Cups and Plastic Bottles at 4&deg;C and 25&deg;C,&rdquo; <i>Can J Hosp Pharm</i> 2010, 63(5):366-72.<span class=\"pubmed-id\">22479004</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233317\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vancocin HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (20): $1,887.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (20): $3,480.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vancomycin HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (20): $626.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (20): $1,154.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (First-Vancomycin 25 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (150 mL): $82.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (First-Vancomycin 50 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (210 mL): $133.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vancomycin HCl in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/100ML 5% (100 mL): $13.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/200ML 5% (200 mL): $36.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/250ML 5% (250 mL): $14.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25GM/250ML 5% (250 mL): $16.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5GM/250ML 5% (250 mL): $22.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5GM/500ML 5% (500 mL): $23.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75GM/500ML 5% (500 mL): $22.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/500ML 5% (500 mL): $21.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL 5% (100 mL): $7.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750MG/150ML 5% (150 mL): $13.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vancomycin HCl in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/150ML 0.9% (150 mL): $17.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/200ML 0.9% (200 mL): $28.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/250ML 0.9% (250 mL): $18.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25GM/150ML 0.9% (150 mL): $16.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25GM/250ML 0.9% (250 mL): $19.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5GM/150ML 0.9% (150 mL): $18.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5GM/250ML 0.9% (250 mL): $22.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5GM/500ML 0.9% (500 mL): $23.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75GM/250ML 0.9% (250 mL): $21.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75GM/300ML 0.9% (300 mL): $26.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75GM/500ML 0.9% (500 mL): $25.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/250ML 0.9% (250 mL): $22.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/500ML 0.9% (500 mL): $25.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5GM/500ML 0.9% (500 mL): $29.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL 0.9% (100 mL): $8.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750MG/150ML 0.9% (150 mL): $13.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750MG/250ML 0.9% (250 mL): $14.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Firvanq Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (150 mL): $113.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (150 mL): $150.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Vancomycin HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $255.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 g (1): $480.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $3.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (1): $11.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (1): $7.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 mg (1): $95.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Vancomycin+SyrSpend SF PH4 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (120 mL): $656.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233320\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adimicin (HR);</li>\n      <li>Aekovan (PH);</li>\n      <li>Celovan (HK);</li>\n      <li>Citerin (MX);</li>\n      <li>Covan (BD);</li>\n      <li>Covancin (IN);</li>\n      <li>Cytovan (IN);</li>\n      <li>Dhacocin (MY, SG);</li>\n      <li>Edicin (BG, CZ, EE, HR, RO, RU, SK, TH, TR, UA);</li>\n      <li>Estavam (MX);</li>\n      <li>Forstaf (IN);</li>\n      <li>Icoplax (AR, PE);</li>\n      <li>Kovan (CL);</li>\n      <li>Levovanox (IT);</li>\n      <li>Mersa (PH);</li>\n      <li>Normedia (SE);</li>\n      <li>Riveran (AR, PE);</li>\n      <li>Tancofeto (MY);</li>\n      <li>Vacsol (MX);</li>\n      <li>Vagran (VE);</li>\n      <li>Vamysin (BE);</li>\n      <li>Vanauras (MX);</li>\n      <li>Vanaurus (EC);</li>\n      <li>Vanbiotic (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vancard (BD);</li>\n      <li>Vancep (ID);</li>\n      <li>Vancin (BD);</li>\n      <li>Vancin-S (TH);</li>\n      <li>Vanco-SAAR (DE);</li>\n      <li>Vanco-Teva (IL);</li>\n      <li>Vancoavenir (IL);</li>\n      <li>Vancobac (BD);</li>\n      <li>Vancocid (TH);</li>\n      <li>Vancocin (AE, AT, AU, BB, BG, EG, HU, IE, JO, LK, MT, NL, RU, SA, SI, VN, ZA);</li>\n      <li>Vancocin CP (AU, CN, IN, MX, PK, TW);</li>\n      <li>Vancocin HCl (BF, BJ, CH, CI, DK, ET, GB, GH, GM, GN, HK, KE, LR, MA, ML, MR, MU, MW, NE, NG, PH, SC, SD, SE, SL, SN, TN, TW, TZ, UG, ZM, ZW);</li>\n      <li>Vancocina (IT);</li>\n      <li>Vancocine (FR);</li>\n      <li>Vancodex (ID);</li>\n      <li>Vancoled (AE, EG, KR, KW, VN);</li>\n      <li>Vancolon (AE, BH, ET, KW, LB, PH, QA, SA);</li>\n      <li>Vancomax (PE, PY);</li>\n      <li>Vancomet (PH);</li>\n      <li>Vancomicina (DO);</li>\n      <li>Vanconix (BD);</li>\n      <li>Vancorin (TR);</li>\n      <li>Vancorus (RU);</li>\n      <li>Vancosam (LK);</li>\n      <li>Vancosan (BR, FI, IS, LT, LV);</li>\n      <li>Vancotech (LK);</li>\n      <li>Vancotek (AR);</li>\n      <li>Vancotex (MY);</li>\n      <li>Vancotrat (BR);</li>\n      <li>Vancox (MX);</li>\n      <li>Vancozin (KR);</li>\n      <li>Vanlyo (TW);</li>\n      <li>Vanmicira (CZ);</li>\n      <li>Vantocil (ID);</li>\n      <li>Varedet (AR, PE, PY, UY);</li>\n      <li>Voncon (GR);</li>\n      <li>Vondem (GR);</li>\n      <li>Voxin (GR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Al-Jeraisy M, Phelps SJ, Christensen ML, Einhaus S. Intraventricular vancomycin in pediatric patients with cerebrospinal fluid shunt infections. <i>J Pediatr Pharmacol Ther</i>. 2004;9(1):36-42.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amaker RD, DiPiro JT, and Bhatia J, &quot;Pharmacokinetics of Vancomycin in Critically Ill Infants Undergoing Extracorporeal Membrane Oxygenation,&quot; <i>Antimicrob Agents Chemother</i>, 1996, 40(5):1139-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/8723454/pubmed\" target=\"_blank\" id=\"8723454\">8723454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, et al, eds. <i>Red Book: 2009 Report of the Committee on Infectious Diseases</i>. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists Committee on Obstetric Practice, &quot;ACOG Committee Opinion No. 485: Prevention of Early-Onset Group B Streptococcal Disease in Newborns,&quot; <i>Obstet Gynecol</i>, 2011, 117(4):1019-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21422882/pubmed\" target=\"_blank\" id=\"21422882\">21422882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society and Infectious Diseases Society of America, &quot;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&quot; <i>Am J Respir Crit Care Med</i>, 2005, 171(4):388-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15699079/pubmed\" target=\"_blank\" id=\"15699079\">15699079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, 154.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bateman DA, Thomas W, Parravicini E, Polesana E, Locatelli C, Lorenz JM. Serum creatinine concentration in very-low-birth-weight infants from birth to 34-36 wk postmenstrual age. <i>Pediatr Res</i>. 2015;77(5):696-702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25675426 /pubmed\" target=\"_blank\" id=\"25675426 \">25675426 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benner KW, Worthington MA, Kimberlin DW, et al, &quot;Correlation of Vancomycin Dosing to Serum Concentrations in Pediatric Patients: A Retrospective Database Review,&quot; <i>J Pediatr Pharmacol Ther</i>, 2009, 14:86-93.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourget P, Fernandez H, Delouis C, et al, &quot;Transplacental Passage of Vancomycin During the Second Trimester of Pregnancy,&quot; <i>Obstet Gynecol</i>, 1991, 78(5 Pt 2):908-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/1923224/pubmed\" target=\"_blank\" id=\"1923224\">1923224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buck ML, &quot;Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation: Implications for Drug Therapy of Neonates,&quot; <i>Clin Pharmacokinet</i>, 2003, 42(5):403-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/12739981/pubmed\" target=\"_blank\" id=\"12739981\">12739981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buck ML, &quot;Vancomycin Pharmacokinetics in Neonates Receiving Extracorporeal Membrane oxygenation,&quot; <i>Pharmacotherapy</i>, 1998, 18(5):1082-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9758319/pubmed\" target=\"_blank\" id=\"9758319\">9758319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capparelli EV, Lane JR, Romanowski GL, et al, &quot;The Influences of Renal Function and Maturation on Vancomycin Elimination in Newborns and Infants,&quot; <i>J Clin Pharmacol</i>, 2001, 41(9):927-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/11549096/pubmed\" target=\"_blank\" id=\"11549096\">11549096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease, revised guidelines from CDC, 2010. <i>MMWR Recomm Rep</i>. 2010; 59(RR-10):1-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21088663/pubmed\" target=\"_blank\" id=\"21088663\">21088663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chang D, &quot;Influence of Malignancy on the Pharmacokinetics of Vancomycin in Infants and Children,&quot; <i>Pediatr Infect Dis J</i>, 1995, 14(8):667-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/ 8532423 /pubmed\" target=\"_blank\" id=\" 8532423 \"> 8532423 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chang D, Liem L, and Malogolowkin M, &quot;A Prospective Study of Vancomycin Pharmacokinetics and Dosage Requirements in Pediatric Cancer Patients,&quot; <i>Pediatr Infect Dis J</i>, 1994, 13(11):969-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/7845750/pubmed\" target=\"_blank\" id=\"7845750\">7845750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen SH, Gerding DN, Johnson S, et al, &quot;Clinical Practice Guidelines for <i>Clostridium difficile</i> Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA),&quot; <i>Infect Control Hosp Epidemiol</i>, 2010, 31(5):431-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/20307191/pubmed\" target=\"_blank\" id=\"20307191\">20307191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cook AM, Mieure KD, Owen RD, Pesaturo AB, Hatton J. Intracerebroventricular administration of drugs. <i>Pharmacotherapy</i>. 2009;29(7):832-845.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19558257/pubmed\" target=\"_blank\" id=\"19558257\">19558257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Hoog M, Mouton JW, and van den Anker JN, &quot;Vancomycin: Pharmacokinetics and Administration Regimens in Neonates,&quot; <i>Clin Pharmacokinet</i>, 2004, 43(7):417-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15139793/pubmed\" target=\"_blank\" id=\"15139793\">15139793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frymoyer A, Hersh AL, Benet LZ, et al, &quot;Current Recommended Dosing of Vancomycin for Children With Invasive Methicillin-Resistant <i>Staphylococcus aureus</i> Infections Is Inadequate,&quot; <i>Pediatr Infect Dis J</i>, 2009, 28(5):398-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19295465/pubmed\" target=\"_blank\" id=\"19295465\">19295465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frymoyer A, Hersh AL, El-Komy MH, et al. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. <i>Antimicrob Agents Chemother</i>. 2014;58(11):6454-6461.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25136027 /pubmed\" target=\"_blank\" id=\"25136027 \">25136027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &quot;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&quot; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and &quot;red man syndrome&quot;: comparison of 1- and 2-hour infusions. <i>Antimicrob Agents Chemother</i>. 1990;34(4):550-554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/1693055/pubmed\" target=\"_blank\" id=\"1693055\">1693055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. December 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed March 17, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. <i>Clin Pharm</i>. 1990;9(9):711-715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2225752/pubmed\" target=\"_blank\" id=\"2225752\">2225752</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure.<i> Pediatr Infect Dis J</i>. 2013;32(4):e155-163.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23340565 /pubmed\" target=\"_blank\" id=\"23340565 \">23340565 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonard MB, Koren G, Stevenson DK, et al, &quot;Vancomycin Pharmacokinetics in Very Low Birth Weight Neonates,&quot; <i>Pediatr Infect Dis J</i>, 1989, 8(5):282-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2657617/pubmed\" target=\"_blank\" id=\"2657617\">2657617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &quot;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children: Executive Summary,&quot; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marsot A, Boulamery A, Bruguerolle B, et al, &quot;Vancomycin: A Review of Population Pharmacokinetic Analyses,&quot; <i>Clin Pharmacokinet</i>, 2012, 51(1):1-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22149255/pubmed\" target=\"_blank\" id=\"22149255\">22149255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mart&iacute; R, Rosell M, Pou L, et al, &quot;Influence of Biochemical Parameters of Liver Function on Vancomycin pharmacokinetics,&quot; <i>Pharmacol Toxicol</i>, 1996, 79(2):55-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/8878246/pubmed\" target=\"_blank\" id=\"8878246\">8878246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matzke GR, Zhanel GG, and Guay DRP, &quot;Clinical Pharmacokinetics of Vancomycin,&quot; <i>Clin Pharmacokinet</i>, 1986, 11(4):257-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/3530582/pubmed\" target=\"_blank\" id=\"3530582\">3530582</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al, &quot;Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2009, 49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. <i>Br J Clin Pharmacol</i>. 2005;60(3):265-275.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/16120065 /pubmed\" target=\"_blank\" id=\"16120065 \">16120065 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfausler B, Haring HP, Kampfl A, Wissel J, Schober M, Schmutzhard E. Cerebrospinal fluid (CSF) pharmacokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. <i>Clin Infect Dis</i>. 1997;25(3):733-735.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9314470 /pubmed\" target=\"_blank\" id=\"9314470 \">9314470 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reyes MP and Ostrea EM Jr, &quot;Toxicity of Vancomycin Given During Pregnancy (Reply),&quot; <i>Am J Obstet Gynecol</i>, 1990, 163(4 Pt 1):1376.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reyes MP, Ostrea EM Jr, Cabinian AE, et al, &quot;Vancomycin During Pregnancy: Does It Cause Hearing Loss or Nephrotoxicity in the Infant?&quot; <i>Am J Obstet Gynecol</i>, 1989, 161(4):977-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2801848/pubmed\" target=\"_blank\" id=\"2801848\">2801848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodvold KA, Everett JA, Pryka RD, and Kraus DM, &quot;Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children,&quot; <i>Clin Pharmacokinet</i>, 1997, 33(1):32-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9250422/pubmed\" target=\"_blank\" id=\"9250422\">9250422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rybak MJ, Albrecht LM, Boike SC, et al, &quot;Nephrotoxicity of Vancomycin, Alone and With an Aminoglycoside,&quot; <i>J Antimicrob Chemother</i>, 1990, 25(4):679-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2351627/pubmed\" target=\"_blank\" id=\"2351627\">2351627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rybak M, Lomaestro B, Rotschafer JC, et al, &quot;Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists,&quot; <i>Am J Health-Syst Pharm</i>, 2009, 66(1):82-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19106348/pubmed\" target=\"_blank\" id=\"19106348\">19106348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schutze GE, Willoughby RE, Committee on Infectious Diseases, American Academy of Pediatrics. <i>Clostridium difficile</i> infection in infants and children. <i>Pediatrics</i>. 2013;131(1):196-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23277317 /pubmed\" target=\"_blank\" id=\"23277317 \">23277317 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &quot;Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stockmann C, Hersh AL, Roberts JK, et al. Predictive performance of a vancomycin population pharmacokinetic model in neonates. <i>Infect Dis Ther</i>. 2015;4(2):187-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25998107 /pubmed\" target=\"_blank\" id=\"25998107 \">25998107 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of <i>Clostridium difficile</i> infections. <i>Am J Gastroenterol</i>. 2013;108(4):478-498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23439232 /pubmed\" target=\"_blank\" id=\"23439232 \">23439232 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Szymusiak-Mutnick BA, Ross MB. Minimizing the occurrence of red-man syndrome. <i>Am J Health Syst Pharm</i>. 1996;53(17):2098.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/8870903/pubmed\" target=\"_blank\" id=\"8870903\">8870903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41:1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &quot;Practice Guidelines for the Management of Bacterial Meningitis,&quot; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vancocin (vancomycin) [prescribing information]. Exton, PA: ViroPharma Incorporated; December 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, (32 Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12874 Version 213.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50667383\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F233330\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F233331\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050536\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445215\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050528\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F233306\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F233291\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F45040033\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F51063159\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050541\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F1671784\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050540\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F233387\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F233384\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F233314\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F233295\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300205\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F233300\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F233302\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6833811\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050535\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1050539\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F233294\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F233313\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F14320792\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F233317\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F233320\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12874|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin: Drug information</a></li><li><a href=\"topic.htm?path=vancomycin-patient-drug-information\" class=\"drug drug_patient\">Vancomycin: Patient drug information</a></li></ul></div></div>","javascript":null}